GLPwatch

A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.

NCT04153929 · Completed

Last updated 2026-05-28

This clinical trial is testing different doses of the medication BI 456906 in adults with type 2 diabetes to see how it affects their blood sugar levels over 16 weeks.

Status Completed The study has finished.
Phase Phase 2 Tests whether it works and watches safety in a moderate group.
Type Interventional (clinical trial)
Design Randomized, quadruple-blind treatment study
Participants 413 people
Who can join Ages 18–75 · all sexes
Timeline Started 2020-04 · est. completion 2021-11
Where 80 sites · Australia, Austria, Canada, Czechia, Germany, Hungary, New Zealand, Poland, Puerto Rico, South Korea, Spain, Taiwan, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT04153929 ↗

Description as written by the study sponsor.

This study is open to adults with type 2 diabetes who take metformin but still have too high blood sugar. The purpose of the study is to find the best dose of BI 456906 that reduces blood sugar. The study also looks at whether BI 456906 helps the participants lose weight. Participants are in the study for about 23 weeks. During this time, most participants visit the study site about 13 times. Some participants visit the study site about 20 times. At the start of the study, the participants are put into 7 groups. The participants in groups 1 to 6 get injections under the skin once or twice every week. Some participants get different doses of BI 456906 and other participants get placebo. Placebo injections look like the BI 456906 injections, but contain no medicine. Participants in group 7 get semaglutide injections every week. Semaglutide is another medicine for adults with type 2 diabetes. During the study, the doctors regularly take blood samples from the participants and measure their body weight. The changes in blood sugar levels and body weight are compared between the groups. The doctors also check the general health of the participants.

Treatments tested

Main thing measuredAbsolute Change in HbA1c From Baseline to 16 Weeks
SponsorBoehringer Ingelheim
Conditions studiedDiabetes Mellitus, Type 2
GLP-1 drugs

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04153929 ↗